Tablet formulations contain 50-79 wt.% allopurinol (4-hydroxypyrazolo (3,4-d)pyrimidine, a xanthine oxidase inhibitor used in a treatment of gout and other hyperuricaemic disorders) having a particle size of less than 40 mu m (pref. 15-38 mu m); 15-35 wt.% inert fillers; 5-15 wt.% tablet disintegrating agents; and 1-10 wt.% granulating agents. The high proportion of active ingredient in the formulation renders it suitable for high dosage regimes. Despite the high allopurinol content, the formulation gives tablets of satisfactory hardness and abrasion-resistance having satisfactory disintegration characteristics.
展开▼
